T he role of the sympathetic nervous system in the development and maintenance of hypertension has long been recognized, 1,2 and for decades, extensive research has demonstrated the effects of renal denervation on hypertension and other disease states. 3, 4, 5, 6, 7 It has been well established that kidneys act both as generators and recipients of sympathetic signals 8 transferred bidirectionally through afferent or efferent sympathetic fibers. Both afferent and efferent sympathetic fibers course through the adventitia of the renal artery and are thus amenable to thermal injury using transvascular techniques. 9 Resistant hypertension, defined as uncontrolled hypertension with at least 3 antihypertensive medications, of which one is a diuretic, is an emerging problem with unmet medical needs. Given resistance to drug therapy, activation of sympathetic nervous system, the role of renal nerves in the development of hypertension, and the ease of approach of the sympathetic fibers by catheter-based techniques, resistant hypertension is the optimal candidate for interventional approaches. 10, 11, 12 Most of the published catheter-based renal denervation studies [13] [14] [15] [16] [17] [18] used single-tip catheters to achieve renal denervation and demonstrated encouraging but inconsistent results. The first-in-man study, Symplicity HTN-1, 13 demonstrated a small reduction in office blood pressure (BP) early on, which improved with time, thus creating the impression of delayed response after renal denervation. However, published data from these studies present different numbers of patients at different time points, making the results difficult to interpret. The second study, Symplicity HTN-2, 14 was a placebo-controlled but unblinded study that showed a similar pattern of BP reduction as HTN-1, but did not show a placebo effect. In both studies (HTN-1 Abstract-Renal denervation has emerged as a novel approach for the treatment of patients with drug-resistant hypertension. To date, only limited data have been published using multielectrode radiofrequency ablation systems.
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and HTN-2), only a portion of patients underwent ambulatory monitoring, which showed less BP reduction as compared with office BP. Home BP measurements were reported in a small number of patients in HTN-1. Most of the studies published since then followed similar protocol design and showed similar results as HTN-1 and HTN-2, but other studies showed no effect on BP. 19, 20 Most studies that included ambulatory monitoring showed a substantial difference in the magnitude of BP response between office and ambulatory measurements. 21 It was expected that Symplicity HTN-3, a randomized, blinded, shamcontrolled study that enrolled 535 patients with drug-resistant hypertension, would settle these disparities. Recently, however, it was announced that the study failed to achieve its primary efficacy end point, although the study met its primary safety objective. Results have recently been published. 22 One speculation is that the Symplicity single-tip catheter failed to achieve complete circumferential denervation. Data using multielectrode ablation systems, with more predictable lesion patterns, are limited. EnligHTN I was the first-in-human study, using a multielectrode ablation system, in patients with drug-resistant hypertension. The 6-month data were previously published. 23 The 12-month data with complete analysis of efficacy and safety information including office, 24-hour ambulatory, and home BP measurements are reported in this article. Although the study is unblinded and single arm, it is the first report with a complete set of BP data (office, ambulatory, and home).
Study Population and Methods
Detailed methods for this study have been previously published. 23 In brief, the study enrolled 46 patients who met standard criteria of resistant hypertension. The primary efficacy end point was office BP change from baseline for patients who underwent the renal denervation procedure. The primary safety objective was the rate of adverse events. Efficacy and safety end points were to be collected at 1, 3, 6, 12, 18, and 24 months. The study protocol was approved by the ethics committee of each participating center, and informed consent was obtained from all patients. The study is registered with Clinical Trials Registry (NCT01438229). The trial is sponsored by St Jude Medical, St Paul, MN.
Inclusion and Exclusion Criteria
Patients with resistant hypertension and an office systolic BP that remained consistently ≥160 mm Hg (≥150 mm Hg for patient with type II diabetes mellitus) despite stable use of ≥3 antihypertensive medications were eligible for the study. Complete inclusion and exclusion criteria have been previously described.
23
BP Measurements
Office BP measurements were taken at every study visit using a validated automatic oscillometric device (Omron Healthcare, Bannockburn, IL). Printed recordings were obtained for documentation. Patients were seated in a quiet room for at least 5 minutes, with the back supported and legs uncrossed. Ambulatory BP monitoring was performed for 24 hours using standardized techniques and validated equipment (Spacelabs 90217 Ultralite Ambulatory Blood Pressure monitors; Spacelab Healthcare, Issaqua, WA). Home BP measurements were taken twice daily (in triplicate) at the same time each day (morning and evening) using BP-measuring devices that were provided and have been tested and validated according to the revised British Hypertension Society or the European Society of Hypertension protocol (Omron Healthcare). Patients were asked to monitor home BP daily for 2 weeks before the procedure and for 2 weeks before each study visit.
EnligHTN Renal Denervation System
The renal denervation procedure was performed as previously described 23 using the St Jude EnligHTN renal denervation system (St Jude Medical; Figure S1 in the online-only Data Supplement).
Statistical Analysis
No sample size calculation was undertaken in this first-in-human study to evaluate safety and efficacy. All continuous parameters were summarized using mean, standard deviation, and confidence intervals.
Normality of data was verified with the use of box plots and the Kolmogorov-Smirnov normality test. For normally distributed data, comparisons of primary and secondary outcomes between time points were analyzed using paired t tests. Correlations between variables were performed using Pearson correlation coefficient. In cases where the data were not normally distributed, the nonparametric Wilcoxon signed-rank test was used to analyze the data. All categorical parameters were summarized using frequencies and percentages. Statistical analyses were performed using SAS 9.2 or higher (by SAS Institute, Inc, Cary, NC). Statistical significance was achieved if a 2-sided test obtained a P value <0.05.
Role of the Sponsor
The sponsor of the study (St Jude Medical) provided trial funding, contributed in the design of the study, data analysis, and review of the article. The corresponding author had full access to all data and had final responsibility for drafting and submitting the article for publication.
Results
A total of 46 patients underwent the renal denervation procedure. Baseline characteristics are shown in Table S1 . The average age was 60±10 years with an average body mass index of 32±5 kg/m 2 ; 33% were women, and all but 1 patient were whites. Comorbidities included coronary artery disease 20%, type II diabetes mellitus 33%, hyperlipidemia 59%, and sleep apnea 30%. The average serum creatinine was 78±17 μmol/L, and the average estimated glomerular filtration rate was 87±19 mL/min per 1.73 m 2 . The average office BP at baseline was 176±16/96±14 mm Hg, and the 24-hour ambulatory BP was 150±14/83±13 mm Hg. The average baseline BP obtained from home measurements was 158±16/90±12 mm Hg. The average number of antihypertensive medications used for this group of patients was 4.7±1.0, and all but 1 patient (prior allergy to diuretics) received diuretic therapy. All patients were on ≤3 of the 4 major classes of antihypertensive medications (angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers, β-blockers, calcium channel blockers, and diuretics). Approximately 13% of patients were receiving aldosterone antagonists at study entry and during follow-up. The percentage of patients on each medication class at baseline and at each follow-up time point is shown in Table 1 .
Adverse Events
No serious or life-threatening adverse events were noted during or immediately after the procedure. There were no access site complications and no renal artery dissections, perforations, or occlusions. Serious adverse events that were deemed possibly related to the procedure or device were reported in 3 (6.5%) patients through 12 months of follow-up. These events included hypotension, progression of pre-existing renal artery stenosis, and a progression of hypertensive renal disease with an increase in serum creatinine. Minor periprocedural or device-related events were reported as shown in Table S2 . All minor periprocedural events were resolved at follow-up with no consequences.
Evaluation of renal arteries was performed in all patients by computed tomographic angiography at 6 months. Two patients with pre-existing renal artery stenosis at baseline experienced asymptomatic worsening at 6 months. In 1 patient, progression of renal artery stenosis was adjudicated as nonserious, and in the second as serious. In this second patient, renal artery stenosis progressed to 75% at 10 months of follow-up as confirmed by angiography. The worsened stenosis was treated with stent implantation, and the procedure was uneventful.
Renal function was assessed using repeated measures of estimated glomerular filtration rate, serum creatinine, cystatin C, and albumin-to-creatinine ratio. From baseline to 6 months, serum creatinine and estimated glomerular filtration rate indicated a trend toward declining renal function, but at 12 months, the values returned to baseline. In contrast, cystatin C levels and albumin-to-creatinine ratio showed a trend toward improvement of renal function that was statistically significant, and it was sustained ≤12 months (Table 2) .
Effect on BP (Office and Ambulatory Measurements)
At baseline, office BP averaged 176±16/96±14 and heart rate 71±12 beats per minute. After renal denervation, office BP decreased by −28/−10, −27/−10, and −26/−10 at 1, 3, and 6 months and remained consistent at 12 months with a reduction of −27/−11 mm Hg (P<0.001; Figure 1 ). Office heart rate was reduced by −2±13, −4±10, −4±11, and −5±7 at 1, 3, 6, and 12 months, respectively. The average 24-hour ambulatory BP was 150±14/83±13 at baseline and decreased by −10/−5 mm Hg at 1, 3, and −10/−6 at 6 months (P<0.001). At 12 months, the average ambulatory BP reduction was less, but Figure 2 ). Because of the possibility that not all patients met the criteria of true resistance at baseline, we separated patients into 2 groups: those with elevated office and 24-hour ambulatory or daytime BP (true resistant; n=41) and those with elevated office, but normal 24-hour ambulatory BP (pseudoresistant; n=5; Figure S2 ). In patients with true resistant hypertension, baseline office BP was 177±17/97±15, and in patients with pseudoresistant hypertension, it was 172±9/92±5 mm Hg. Twenty-four-hour ambulatory BP was At baseline, all but 2 patients had office systolic BP ≥160 mm Hg; at 6 months, 69% had systolic BP <160 mm Hg; and at 12 months, 76% of patients had systolic BP <160 mm Hg ( Figure S3 ).
Home Measurements
At baseline, the 14-day average home BP was 158±16/90±12 mm Hg. Morning BPs were consistently higher (3 mm Hg) than evening BPs. The weekly averaged BPs at week 2 and week 1 preprocedure and 2 weeks before each follow-up visit were remarkably consistent and reproducible ( Figure 3) . The 14-day average home BP for the first month after the procedure was 149±19/87±12 mm Hg. Reduction from baseline was −9/−4 mm Hg. Similarly at 3 and 6 months, the 14-day average BP was 149±19/84±10 and 147±20/82±101 mm Hg, demonstrating a stable −8/−5 and −10/−7 mm Hg BP reduction from baseline. At 12 months, the 14-day average BP remained stable (147±19/84±12), maintaining a BP reduction of −11/−6 mm Hg from baseline. The 14-day (before each visit) average heart rate changed little over time compared with the baseline heart rate: −1±7, 1±8, 0.5±7, and −0.2±7 beats per minute at 1, 3, 6, and 12 months of follow-up per patient diary data. Figure 4 shows average office, 24-hour ambulatory BP, daytime ambulatory BP, and 14-day average home BP measures at baseline and at 1, 3, 6, and 12 months post renal denervation. At baseline, office systolic BP was 26, 23, and 17 mm Hg higher than the 24 hour ambulatory BP, daytime ambulatory BP and 14-day average home BP respectively. Proportional differences were noted in diastolic BPs. At month 1 and thereafter office BPs and 14-day average home BP were almost superimposed. The daytime ambulatory BP followed similar pattern as the home BP whereas the 24 hour ambulatory BP was lower possibly because of nocturnal dip. After renal denervation both systolic and diastolic measured either in the office, at home or by ambulatory monitoring fell substantially and remained stable after month 1 thru 12 months. Figure S4 shows the % of responders (≥10 mm Hg reduction in office systolic BP or ≥5 mm Hg in average home or ambulatory BP) or controlled (BP<140/90 mm Hg for office and BP<135/85 mm Hg for ambulatory BP and Home BP) patients by office, average 24 hour ambulatory, daytime ambulatory BP and home BP measurements through 12 months. At 6 months 76%, 68%, 58%, and 56% were responders by office, 24 hour, daytime ambulatory BP, and home BP, respectively and 33%, 46%, 37%, and 25% were controlled. At 12 months 80%, 54%, 61%, and 72% were responders by office, 24 hour, daytime ambulatory, and home BP and 27%, 37%, 33%, and 28% respectively, were controlled (P<0.001 for all). In correlation analysis, baseline office systolic BP and heart rate correlated significantly with BP reduction at 6 months, but only baseline office BP correlated significantly at 12 months ( Figure S5 ). When patients were grouped by baseline systolic BP or baseline heart rate, those with the highest baseline BP had the greatest reduction of office BP, which was sustained through 12 months ( Figure S6) .
In most patients the antihypertensive regimen remained unchanged during the follow up period. However, some changes were made in a few patients as follows: during the first 6-month follow-up period, medication was increased in 4 (9%) and decreased in 6 (13.0%) patients. From 6 months to 12 months, 2 (4%) patients had increases and 3 (7%) had decreases in their antihypertensive medication. Overall changes in medication regimen ≤12 months remained consistent and are shown in Table 1 .
Discussion
EnligHTN I is the first-in-human multicenter study, designed to evaluate the efficacy and safety of a multielectrode ablation system. As such the study had no parallel placebo control arm.
Potential adverse effects are focused on 2 areas: Procedure or device related and effects of renal denervation on renal function. The 12-month data continue to demonstrate acceptable safety of the procedure. As previously reported the procedure-related adverse events were minor bleeds, bruising or small hematomas at the puncture site, and some vasospasm of the renal artery after the renal denervation procedure. There were no major vascular access events and no significant acute changes in renal anatomy. There were two patients who showed some progression of renal artery stenosis, but in only one patient progression became clinically relevant. That patient had a preexisting osteal left renal artery lesion (≈30%) at baseline, which became progressively worse requiring renal artery stenting. Renal artery stenosis post denervation is a legitimate concern, because the denervation procedure causes endothelial disruption, at least temporarily and creates a substrate for atherosclerosis development. Fortunately only few cases have been reported to date as device or procedure related. 24, 25 Close follow up of the cases performed around the world is needed to collect more information on this important issue.
Renal function was serially assessed in this trial. After renal denervation both serum creatinine and estimated glomerular filtration rate indicated a trend toward worsening renal function, but between 6 and 12 months the trend was reversed and both indexes returned toward baseline. Overall there was no significant change compared with baseline suggesting that renal denervation has no detrimental effects on renal function. It is well known from animal 26 and human studies 27 that renal denervation results in improvement in renal blood flow which may result in improved clearance, but it may also expose the renal microvessels to higher pressures thus influencing endothelial function. The signals so far, however, suggest that there is no short-term harmful effect. In fact, data from this study demonstrate improvement in cystatin-C levels and in the albumin/creatinine ratio, which continued to 12 months. Cystatin-C is an acute kidney injury reactant and lower levels indicate an improved prognosis. 28, 29 Similarly improved albumin/creatinine ration indicates improvement in renal endothelial function or lower perfusion pressures. Both findings can be explained from BP lowering, but they may also be because of decrease of sympathetic influence on renal microvessels and reduced plasma renin activity. 30, 31 This is the first report to present complete data on changes in office, ambulatory, and home BP measurements after renal denervation. The 12-month data indicate that office BP reduction continued at the same level as in previous time points (−27/−11 mm Hg). This finding is at variance with previous reports 13, 14 that actually found improvement in office BP response with time. The ambulatory BP reduction was maintained, but at slightly lower level (−7/−4 mm Hg). This is because of the fact that fewer patients (only 35/46) accepted to have an ambulatory BP at 12 months, and in some patients, BP increased after the 6-month visit. In the present analysis, we also examined BP response in patients with true resistant hypertension (elevated both office and ambulatory BP measurements; n=41) and in patients with pseudoresistance (elevated office BP, but normalized ambulatory BP measurements; n=5). Patients with pseudoresistant hypertension had numerically greater reduction in office BP as compared with true resistant hypertension, despite the fact that they started from a lower baseline office BP, but this can most likely be attributed to apparent white-coat effect. The average 24-hour ambulatory BP reduction was significantly greater in the true resistant as compared with pseudoresistant patients and similar to what has been reported in other studies. 18 In this article, we also analyzed the home BP measurements. To our knowledge, this is the first report in the renal denervation literature to present complete home BP measurement data from patients at baseline and during follow-up time points. The strength of home measurements is the fact that when patients are in their usual environment, measurements are not affected by external factors and measurement can be taken on a daily basis, thus eliminating day-to-day variability. Morning pressures were consistently higher than afternoon BPs at baseline and at all follow-up time points. This observation is supported by the literature, 32 and the early morning rise in BP is a wellknown phenomenon. 33 Measurements for the last 2 weeks before the procedure were summarized and averaged, thus smoothing out any day-to-day variability. At baseline, home systolic and diastolic BP was elevated consistently at similar level for weeks 3, 2, and 1 before the procedure, indicating stable and consistent baseline and no continuing effect of any regimen changes that might have been made before enrollment in the study. After renal denervation, home systolic and diastolic BP dropped by ≈11/5 mm Hg and remained at the same level, with minor variability ≤12 months.
The BP reduction seen with home BP measurements is very similar with the reductions seen on daytime ambulatory BP measurements. Of note, both these techniques represent average BP measurements over a period of time: ambulatory BP represents average of ≈70 BP measurements in a 24-hour interval, whereas home BP measurements average ≈84 BP measurements over 14-day intervals. Both of these techniques are good representations of the prevailing BP at the time interval monitored. Home BP measurements correlated closely with daytime ambulatory BP monitoring and after month 1 post denervation with office BP measurements. Similar differences between office BP and ambulatory BP reductions have been reported in previously published studies 13, 14, 18, 34 and have been scrutinized, 21, 35 but comparisons between office and home measurements have been limited to a small number of patients in Symplicity HTN-1. 13 Small differences are expected and have been reported in the drug treatment literature. In a meta-analysis, Ishikawa et al 36 reviewed 30 articles published before 2008 that included a total of 6794 patients and reported changes in both office BP and home BP measurements. Seven studies also included ambulatory BP measurements. They found that office BP reductions were only 3/2 mm Hg greater than home BP reductions, and home BP reduction was only slightly higher than 24-hour and daytime ambulatory BP reduction of ≈1 mm Hg. The question then is why the disparity between office BP reduction and ambulatory BP or home BP measurements in this study. Figure 4 plots changes in office, home, and ambulatory BP measurements over time. It is obvious that the biggest disparity exists at baseline. Office BP was much higher than the average 24-hour ambulatory BP, daytime ambulatory BP, and the 14-day average home systolic BP. After renal denervation, however, all 4 measures were similar, with the office systolic BP and home systolic BP almost superimposed at 1 month, remaining fairly stable up to 12 months. Daytime systolic ambulatory BP was only a few mm Hg lower and followed the same pattern. Similar patterns were noted in diastolic BP measurements (Figure 4) . The higher baseline office BP can be explained by several factors that may include dayto-day variability, selection bias, first visit alert effect, and white-coat effect. If this assertion is true, the discrepancy in BP response between office and home or ambulatory BP response would be seen also in the placebo or control arm. This cannot be assessed, however, because there are no controls in this first-in-human study. Similar limitations exist for almost all published data to date. In Symplicity HTN-2, 14 there was a placebo arm, but the study was not blinded and as such subject to potential bias. These issues are extensively discussed in a recently published meta-analysis of 31 drug trials enrolling 4121 patients and 23 renal denervation trials enrolling 720 patients, 37 as well as in our review article. 21 Of note, a recently published study 38 (online only) compared the BP-lowering effect of renal denervation to clinically adjusted drug treatment in patients with true resistant hypertension and found that medication adjustment was superior to renal denervation. In fact, the study showed no significant BP-lowering effect after renal denervation. The study, however, included a small number of patients in each group and used a single-tip catheter with the same limitations as discussed above.
We realize that without a blinded, sham-controlled arm, it is difficult to be certain about the magnitude of BP reduction post-renal denervation. In fact it is entirely possible that in a properly designed, sham-controlled study, renal denervation with a multielectrode system may not be better than placebo. It is worth noting, however, that in this study BP reduction is documented by all 3 measures: office, home, and ambulatory BP monitoring. The magnitude of placebo-subtracted BP response, however, still remains to be defined. There are cases that demonstrate impressive BP response (≤120 mm Hg in systolic BP), 39 but others show no response. As of now, data indicate that BP response over time consistently correlates with the level of BP at baseline. Perhaps this clinical variable should be for now a guide of who are the best candidates for renal denervation.
Perspective
At the time of this writing, results of Symplicity HTN-3 22 have just been published. The study failed to demonstrate any difference in BP reduction between the denervated and sham-controlled arms. One explanation of this outcome is that the single-tip device used in the study is operator-dependent, difficult to use, and difficult to ensure consistent, circumferentially placed lesions. In the present study, we used a multielectrode, basket-based ablation system that can deliver lesions in a predetermined fashion that can be placed in a circumferential manner, thus eliminating operator learning curve and minimizing the issue of incomplete denervation. In addition, we placed on average 7 to 8 lesions per renal artery. Measurement of BP at home provided evidence of a stable baseline BP over 2 to 3 weeks before the procedure, thus eliminating day-to-day variability and white-coat effect. Stable baseline for 2 to 3 weeks before the procedure also negates the possibility that there was carry-over effect on BP because of potential changes made in the drug regimen before the 2-week medication screening period. Although the magnitude of BP reduction in office BP is much greater than the ambulatory and home measurements, the fact remains that significant improvement was seen with all 3 measures.
The future of renal denervation as a viable procedure to treat patients with resistant hypertension and perhaps other cardiovascular diseases will depend on the ability of research to demonstrate continued safety and efficacy. Well-designed, blinded, sham-controlled studies addressing safety and efficacy, but also studies addressing hard health outcomes using multielectrode devices, remain necessary. 
